Disposable aScope™2 Uses OV6922 for Minimally Invasive and Accurate Medical Imaging
SANTA CLARA, CA — April 10, 2012 — OMNIVISION Technologies, Inc. (Nasdaq: OVTI), a leading developer of advanced digital imaging solutions, today announced that its OV6922 CMOS image sensor has been designed into Ambu’s aScope 2, a single-use intubation scope intended for medical procedures such as difficult intubation and percutaneous dilatational tracheostomy (PDT). Ambu’s disposable aScope 2 flexible videoscope can reduce the risk of cross-contamination when used to secure the airways of fully anesthetized patients. The aScope 2 is powered by OMNIVISION’s ultra-compact 2.1 mm x 2.3 mm OV6922 CameraChip™ image sensor, which delivers crisp, clear imaging for minimally invasive and sterile medical procedures.
“The most critical benefit of the aScope 2 is its ability to reduce the risk for patients, while increasing overall efficiency for medical personnel,” said Matthew Whitcombe, senior marketing manager – Europe at OMNIVISION. “The OV6922 brings an extremely high level of performance in an affordable, ultracompact package, helping physicians to perform these medical procedures quickly and with greater accuracy.”
“OMNIVISION’s support and expertise in medical imaging has been critical to the successful and timely development of the aScope 2,” said Jens Frimann, vice president of commercial innovation at Ambu. “Thanks to the cooperation of health care professionals around the world and the OV6922’s excellent low-light, low-power performance, we were able to develop a single-use medical device that can improve patient comfort and reduce the cost of medical procedures.”
Built on OMNIVISION’s proprietary OmniPixel® technology, the OV6922 combines a 1/18‑inch optical format with extremely low power consumption to provide the high-quality images required for medical applications like the Ambu aScope 2. The sensor’s impressive 1,000 mV/lux‑sec sensitivity allows the camera to deliver clear NTSC video at 60 fields per second in challenging conditions often encountered in the human respiratory system.
About OMNIVISION
OMNIVISION Technologies (Nasdaq: OVTI) is a leading developer of advanced digital imaging solutions. Its award-winning CMOS imaging technology enables superior image quality in many of today’s consumer and commercial applications, including mobile phones, notebooks, tablets and webcams, digital still and video cameras, security and surveillance, entertainment devices, automotive and medical imaging systems. Find out more at www.ovt.com.
About Ambu
Ambu develops, produces and markets diagnostic and life-supporting devices for hospitals and rescue services. Ambu has three business areas: Airway Management, Patient Monitoring & Diagnostics and Emergency Care. The primary products are ventilation products for artificial respiration, electrodes for ECG tests and neurophysiological tests, and manikins for first aid training. Ambu’s products are sold worldwide. Find out more at www.ambu.com.
Safe-Harbor Language
Certain statements in this press release, including statements regarding the expected benefits, performance, capabilities, and potential market appeal of the OV6922 are forward-looking statements that are subject to risks and uncertainties. These risks and uncertainties, which could cause the forward-looking statements and OMNIVISION’s results to differ materially, include, without limitation: potential errors, design flaws or other problems with OV6922, customer acceptance, demand, and other risks detailed from time to time in OMNIVISION’s Securities and Exchange Commission filings and reports, including, but not limited to, OMNIVISION’s annual report filed on Form 10‑K and quarterly reports filed on Form 10‑Q. OMNIVISION expressly disclaims any obligation to update information contained in any forward-looking statement.
OMNIVISION® and the OMNIVISION logo are registered trademarks of OMNIVISION Technologies, Inc. CameraChip™ and OmniPixel® are trademarks of OMNIVISION Technologies, Inc. All other trademarks are the property of their respective owners.